NovoCure (NASDAQ:NVCR) Announces Quarterly Earnings Results, Beats Estimates By $0.14 EPS

NovoCure (NASDAQ:NVCR – Get Free Report) issued its quarterly earnings results on Thursday. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.14, FiscalAI reports. The company had revenue of $193.40 million for the quarter, compared to analyst estimates of $182.28 million. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.00%. The business’s revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.33) earnings per share.

Here are the key takeaways from NovoCure’s conference call:

  • Q3 net revenue rose 16% year over year to $193 million, driven by 19% growth in active patients, stronger Optune Gio performance, and contributions from Optune Lua and Optune Pax. The company raised its 2026 revenue guidance to $736 million–$743 million.
  • Optune Gio active patients reached a record 4,729, up 11% year over year, while Optune Lua’s Japan launch gained momentum with 110 Japanese patients and $4 million in quarterly revenue. Management expects Japan to become NovoCure’s second-largest market behind the U.S.
  • The Optune Pax launch faced significant U.S. headwinds after the introduction of daraxonrasib, with practices reportedly overwhelmed by reimbursement appeals and treatment-related skin irritation; Pax ended the quarter with 276 active patients and $3.7 million in revenue. NovoCure expects to rebuild momentum through improved commercial execution, NCCN guideline inclusion, and planned combination studies with KRAS inhibitors.
  • Profitability metrics improved substantially, with adjusted EBITDA of $16 million versus negative $3 million a year earlier and updated full-year adjusted EBITDA guidance of $24 million–$34 million. Management cautioned that quarterly results may fluctuate, but said its next objective is cash-flow breakeven.
  • The FDA is reviewing the Optune Mya application for brain metastases from non-small cell lung cancer, with a decision expected by year-end and a potential early-2027 launch. KEYNOTE-D58 enrollment remains on track for completion by year-end, supporting potential future GBM growth.

NovoCure Trading Down 0.6%

Shares of NovoCure stock traded down $0.07 during mid-day trading on Friday, hitting $13.04. 446,839 shares of the stock were exchanged, compared to its average volume of 1,677,342. The company has a 50-day simple moving average of $15.88 and a 200 day simple moving average of $14.79. The company has a current ratio of 2.89, a quick ratio of 2.70 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -10.01 and a beta of 0.99. NovoCure has a twelve month low of $9.82 and a twelve month high of $21.45.

NovoCure News Roundup

Here are the key news stories impacting NovoCure this week:

  • Positive Sentiment: NovoCure reported third-quarter revenue of $193.4 million, up 15.7% year over year and above the $182.3 million analyst consensus. The company’s adjusted loss of $0.09 per share also beat expectations, while the loss narrowed from $0.33 per share a year earlier. NovoCure Q3 earnings report
  • Positive Sentiment: The company raised its 2026 financial guidance, signaling confidence in ongoing revenue growth and execution. The improved outlook was a favorable element of the earnings release, although investors appear focused on the pace of commercial adoption. NovoCure raises 2026 guidance
  • Positive Sentiment: NovoCure entered a clinical-trial collaboration and supply agreement with Verastem Oncology to evaluate Tumor Treating Fields therapy alongside VS-7375 in pancreatic cancer. The partnership could expand the company’s clinical pipeline and provide another potential application for its technology, though it remains an early-stage opportunity. NovoCure and Verastem collaboration
  • Negative Sentiment: Management said adoption of Optune Pax has been slower because of Revolution Medicines’ daraxonrasib, raising concerns that competing pancreatic-cancer treatment options could delay or limit uptake. Wedbush characterized the treatment as a potential market disruption rather than direct competition, but the issue appears to have overshadowed the earnings beat. Optune Pax adoption and daraxonrasib

Wall Street Analysts Forecast Growth

Several research analysts have commented on NVCR shares. Wall Street Zen cut shares of NovoCure from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Zacks Research raised shares of NovoCure from a “strong sell” rating to a “hold” rating in a report on Friday, July 24th. Weiss Ratings restated a “sell (d-)” rating on shares of NovoCure in a research note on Thursday, August 27th. Wedbush raised their price objective on shares of NovoCure from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Finally, JPMorgan Chase & Co. initiated coverage on NovoCure in a research report on Monday, July 13th. They set a “neutral” rating and a $17.00 target price on the stock. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $21.20.

Check Out Our Latest Stock Report on NVCR

NovoCure Company Profile

(Get Free Report)

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.

Featured Stories

Earnings History for NovoCure (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.